TELECON & FAX TRANSMITTAL

U.S.NRC		TO:File
United States Nuclear Regulatory Commission		COMPANY: <u>N/A, see below</u> .
Protecting People and the Environment NUCLEAR REGULATORY COMMISSION		
		# PAGES: <u>N/A</u> TEL. : <u>N/A</u>
2443 WARRENVILLE ROAD LISLE, ILLINOIS 60532-4351		FAX #: <u>N/A</u> .
(630) 829-9892 FAX: (630) 515-1078		
CONVERSATION RECORD		DATE DATE DATE DATE] DATE
NAME OF PERSON(S) CONTACTED	TELEPHONE NO.	ORGANIZATION
David J. Keys, PhD	(636) 579-0136	Hannibal Regional Hospital
REPRESENTED PERSON or PERSONS		ORGANIZATION
Joel D. Hassien, M.D., Radiation Safety Officer		Hannibal Regional Hospital
SUBJECT		
License No.: 24-18988-01		Control No.: 574586

SUMMARY

We have conducted a preliminary review your <u>license renewal application</u> and find that we are unable to continue this action until we have received information regarding the following:

- From the application, it is unclear whether PET is being used at the facility. If PET is being used, additional calculations will be required to demonstrate shielding is adequate.
 RESPONSE: The contact person indicated, via phone conversation on May 17, 2011, that the no PET is being used at this facility. No additional response is required.
- References to the 2002 version of NUREG 1556, Volume 9, are outdated. The current version, Revision 2, was published in 2008. Please resubmit pages 3 (under Item 9: Radiation Monitoring Instruments) and 4 (under Item 10: occupational dose), including current reference updates.
 RESPONSE: The contact person submitted reference updates via facsimile dated May 17, 2011. No additional information is required.
- 3. The renewal application referenced the performance of Sentinel Lymph Node Biopsies on page 4 (Item 9: Dose Calibrator), and included a diagram of operating room suites used in sentinel lymph node localization. Please provide additional information regarding the sentinel lymph node procedures performed under 10 CFR 35.200. For example:
 - a. Dosage: Indicate isotope, radioactive quantity, and route of administration.
 - b. Timeframe: How long following dosage administration is the biopsy performed?
 - c. Sample Disposition: How is the sample transferred, analyzed, and/or disposed of? RESPONSE: Licensee indicated that a typical dosage would be 1 mCi Tc-99m, delivered via injection. Biopsies are generally performed a few hours following dosage administration. All samples are taken to pathology, and completed at the hospital. The licensee follows the 2008 Information Notice relating to this procedure. Response is adequate. No additional information is required.

We have not requested that you submit any additional items at this time. No further action is required. Should you wish to submit any additional information, please reference the Control No. 574586, listed at the top of this memo.

Please direct any questions you have to me at (630) 829-9892 or sara.forster@nrc.gov.

NAME OF PERSON DOCUMENTING CONVERSATION

Sara A.B. Forster

SIGNATURE Jana a. B. Foster 06/14/2011 J. Surrans 6/17/11